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Bronchopulmonary dysplasia (BPD) is a common complication of preterm birth that 
contributes significantly to morbidity and mortality in neonatal intensive care units. BPD 
results from life-saving interventions, such as mechanical ventilation and oxygen sup-
plementation used to manage preterm infants with acute respiratory failure, which may 
be complicated by pulmonary infection. The pathogenic pathways driving BPD are not 
well-delineated but include disturbances to the coordinated action of gene expression, 
cell–cell communication, physical forces, and cell interactions with the extracellular 
matrix (ECM), which together guide normal lung development. Efforts to further delineate 
these pathways have been assisted by the use of animal models of BPD, which rely 
on infection, injurious mechanical ventilation, or oxygen supplementation, where histo-
pathological features of BPD can be mimicked. Notable among these are perturbations 
to ECM structures, namely, the organization of the elastin and collagen networks in the 
developing lung. Dysregulated collagen deposition and disturbed elastin fiber organi-
zation are pathological hallmarks of clinical and experimental BPD. Strides have been 
made in understanding the disturbances to ECM production in the developing lung, 
but much still remains to be discovered about how ECM maturation and turnover are 
dysregulated in aberrantly developing lungs. This review aims to inform the reader about 
the state-of-the-art concerning the ECM in BPD, to highlight the gaps in our knowledge 
and current controversies, and to suggest directions for future work in this exciting and 
complex area of lung development (patho)biology.
Keywords: bronchopulmonary dysplasia, extracellular matrix, hyperoxia, mechanical ventilation, collagen, elastin, 
lung development
BRONCHOPULMONARY DYSPLASiA iN CONTeXT
The lung is the key organ of gas exchange in air-breathing mammals. This gas exchange structure 
is derived from the primitive foregut and proceeds through a phase of early (embryonic) develop-
ment (1–3), when the conducting airways and conducting vessels are generated and organized (4). 
Early lung development initiates with the embryonic stage that occurs 4–7 weeks post-conception in 
humans [embryonic day (E)9–E12 in the mouse]. The embryonic stage is followed by the pseudog-
landular stage, which occurs at 5–17 weeks post-conception in humans (E12–E17 in mice). The final 
stage of early lung development is the canalicular stage, occurring at 16–26 weeks post-conception 
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FiGURe 1 | expression pattern of selected extracellular matrix components and remodeling enzymes over the course of early and late lung 
development in mice. The trends illustrated represent a synthesis of the data presented in several publications (8, 9), and span the embryonic and post-natal lung 
maturation period. Abbreviations: BM, basement membrane; E, embryonic day; MMP, matrix metalloproteinase; P, post-natal day.
December 2015 | Volume 2 | Article 912
Mižíková and Morty The ECM in BPD
Frontiers in Medicine | www.frontiersin.org
in humans (E17–E18 in mice), at which point, the process of 
alveolarization begins, which is characterized by the thinning 
of the interstitial tissue (Figure  1). This marks the beginning 
of late lung development, where the distal airways then form 
saccular units in the saccular stage, which is evident in humans 
at 24–38  weeks post-conception [E18-post-natal day (P)4 in 
mice], and these saccular units are divided by secondary septa 
(the process of “secondary septation”) during the alveolar stage, 
which is evident at 36 weeks post-conception to 36 months post-
natal (and beyond) in humans (P4–P28 in mice). The objective 
of late lung development is the production of a large number of 
small alveoli, the principal gas exchange units of the lung. This 
process, which is poorly understood, creates a large surface area 
over which gas exchange takes place. Current knowledge on late 
lung development implicates transcription factors and epigenetic 
effects, which together regulate genetic programs driving lung 
development. These programs work in concert with contact- and 
growth factor-mediated cell–cell communication (5–7) to drive 
lung development. The development of the lung is also driven in 
part by physical forces from breathing motions and the produc-
tion and remodeling of the extracellular matrix (ECM) scaffold.
Multiple diseases are complicated by disturbances to lung 
development. Notable among these is bronchopulmonary dys-
plasia (BPD), which affects prematurely born infants with acute 
respiratory failure that receive oxygen therapy, first described by 
William (Bill) Northway and colleagues in 1967 (10, 11). While 
oxygen supplementation is a life-saving intervention, the associ-
ated oxygen toxicity stunts the post-natal development of the 
lung. This damage to the developing lung is exacerbated by baro-
trauma and volutrauma caused by positive-pressure mechanical 
ventilation, and also by inflammation. Affected infants exhibit 
blunted lung maturation, and BPD represents a significant cause 
of morbidity and mortality in a neonatal intensive care setting 
(11–14). Longitudinal studies suggest that disease sequelae 
persist into adult life (15–17). Examinations of autopsy material 
from patients that have died with BPD have formed the basis of 
hypotheses about pathogenic processes at play that limit alveolari-
zation. These observations include (i) severe disturbances to the 
development of the pulmonary vasculature (18), (ii) changes in 
the cellular structure and composition of the developing alveolar 
units, (iii) increased proteolysis in the alveolar compartments, (iv) 
increased inflammatory cell infiltration, (v) deregulated growth 
factor signaling, and (vi) perturbations to the ECM architecture 
of the developing lung: most notably, the abundance and organi-
zation of collagen and elastin fibers (19–22). These disturbances 
have also been noted in animal models of BPD (23, 24).
It is the objective of this review to highlight key observa-
tions made regarding changes to the ECM architecture of the 
lung – both in clinical BPD and in experimental animal models 
of BPD (referred to herein as “experimental BPD”) – and to inte-
grate these observations into a pathogenic pathway. Furthermore, 
attention will be paid to current controversies in the field, and 
also, to the key gaps in our knowledge, where urgent additional 
work is still to be undertaken.
eARLY STUDieS: THe eCM iN LUNG 
DeveLOPMeNT AND BPD
The ECM represents a very complex network of structurally, 
mechanically, and biochemically heterogeneous components 
(25). The components include the classic “players”: collagen and 
elastin, which constitute 50% (26) and 18% (27), respectively, 
of the lung ECM. This list continues to grow, with fibrillin (28) 
and fibulin (29) glycoproteins, and integrin receptors of ECM 
components (30) being more recent additions. The ECM serves as 
a scaffold that directs lung development, and the ECM structure 
itself is continuously remodeled as lung development proceeds 
(31, 32). As such, the production of ECM components, as well 
as the systems that regulate the deposition and stability of the 
ECM, must be considered. These systems include chaperones and 
enzymes that catalyze the post-translational processing of ECM 
components, as well as systems that destabilize and degrade the 
TABLe 1 | Cellular localization and origin of individual components of extracellular matrix and extracellular matrix remodeling enzymes.
extracellular matrix component Origin/source
epithelial cells Fibroblasts endothelial cells Smooth muscle cells inflammatory cells
Collagen (51–53)
EC-SOD (54, 55)
Elastin (51, 53, 56) (51, 57)
Fibrillin-1 (58, 59)
Fibronectin (58, 60–62) (60) (60) (60, 61)
Fibulin-5/DANCE (63) (64)
Heparan sulfate (65) (66)
Integrins (67–71) (69) (70) (70)
LOX (72, 73) (72, 73)
LOXL1 (72, 73) (72, 73)
LOXL2 (72, 73) (72, 73)
LTBP2 (58)
MMP-1 (74) (74)
MMP-14/MT1-MMP (74–76) (75) (76)
MMP-2 (74, 75, 77, 78) (75) (74) (77)
MMP-9 (74, 77–79) (61) (77, 79)
PLOD1 (80) (80) (80) (80)
PLOD2 (80) (80) (80) (80)
PLOD3 (80) (80) (80) (80)
Tenascin C (81, 82) (81–84) (83, 84) (83) (81)
TGF-β (78) (61)
TGM2/tTG (85–87) (52, 85, 86) (85) (85)
TIMP-1 (75) (75)
TIMP-2 (74, 75) (75) (74)
Numbers in parentheses indicate the citations reporting the identification of the extracellular matrix components or remodeling enzymes in the indicated lung cell types. The citations 
are not all inclusive, and represent only a selection of reports.
EC-SOD, extracellular superoxide dismutase 3; LOX, lysyl oxidase; LoxL1, lysyl oxidase-like 1; LoxL2, lysyl oxidase-like 2; LTBP2, latent TGF-β-binding protein 2; MMP, matrix 
metalloproteinase; MT1, membrane-type 1; PLOD, procollagen-lysine, 2-oxoglutarate 5-dioxygenase; TGF-β, transforming growth factor-β; TGM2, transglutaminase 2; TIMP, tissue 
inhibitor of metalloproteinase; tTG, tissue transglutaminase.
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ECM to facilitate ECM renewal. The remodeling of collagen 
during lung development has been recognized since the early 
1970s (33). Pioneering work by Ron Crystal’s group identified 
the heterogeneity of fibrillar collagens in the lung during lung 
development (34–36). Observations on the dynamic remodeling 
of other collagen types, including basement membrane-type 
IV collagen then followed, in the context of early lung develop-
ment (37, 38). Similarly, pioneering work by Janet Powell and 
Philip Whitney in the early 1980s described changes in lung 
elastin levels as post-natal lung development proceeded (39). 
Subsequent work by Ron Crystal (40) and Robert Rucker’s (41) 
teams highlighted the dynamic expression of tropoelastin during 
the course of post-natal lung development. Building on these 
studies, early work demonstrating that lathyrogens could disturb 
normal lung development (42) highlighted the role of collagen 
and elastin in the post-natal maturation of the lung. Soon to 
follow these reports were key observations of perturbed ECM 
structures in disorders of lung development. Leading work by 
Donald Thibeault and William Truog, in particular, identified 
secondary collagen fibers in the developing parenchyma of neo-
nates with BPD that were “disorganized, tortuous, and thickened” 
(20, 21). Similarly, elastin fibers exhibited an abnormal structure 
in infants with BPD, both in the parenchyma (43–45) and in the 
vasculature (46). These early studies firmly established a role for 
proper lung ECM homeostasis in normal lung development, and 
described severe structural perturbations to the lung ECM that 
accompanied aberrant lung development. Clearly, it is important 
to note that it is sometimes difficult to establish whether the 
perturbations to ECM structure noted in clinical subjects with 
BPD are a cause of aberrant alveolarization, or a consequence of 
blunted lung development. This applies equally to pathological 
material from animals in which BPD has been modeled. Since 
these initial studies reported above, many strides have been made 
in our understanding of the production of the structural compo-
nents of the ECM during post-natal lung development, which will 
be considered in detail below.
KeY STRUCTURAL COMPONeNTS OF 
THe eCM: COLLAGeN AND eLASTiN
Collagen
Collagen is the most abundant protein within the interstitial 
ECM. In the lung, collagen fibers [represented predominantly by 
the fibrillar collagens, collagen type I and III produced by fibro-
blasts (Table 1)] are found in the bronchi, blood vessels, and the 
alveolar septa (35, 47, 48). The abundance of lung parenchymal 
collagen increases over the course of lung development. In mice, 
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gene expression of fibrillar collagens Col1a1 and Col3a1, as well 
as basement membrane collagens Col4a1 and Col4a2, is reported 
to have peaked at P7 (Figure 1). By this time, the collagen had 
formed a delicate interstitial network of fibers that could aid the 
process of alveolar development (8). While Col1a1−/− mice, which 
lack collagen Iα1, died in utero due to the rupture of major blood 
vessels, no abnormalities were noted in lung branching morpho-
genesis in these mice (49, 50). However, elevated levels of other 
fibrillar collagens, including collagen III and V levels, were noted 
in Col1a1−/− mouse embryos, suggesting a possible compensation 
for the loss of functional collagen I (50).
Alterations to the structure and integrity of collagen networks 
have been reported in several animal models of BPD and emphy-
sema, which are diseases of the lung parenchyma that represent 
a failure of alveolar formation and the destruction of existing 
alveoli, respectively (21, 72, 88). Studies in various BPD animal 
models have revealed increased collagen production (Table 2), 
thickened collagen fibers, and increased rigidity of the lung (72, 
88, 89) to be associated with experimental BPD. This is consistent 
with observations made in clinical subjects, where an increased 
number of collagen-positive cells, elevated levels of the fibrillar 
collagens, collagen I and collagen III were observed; and BPD 
patients revealed a specific increase in the collagen I/collagen III 
ratio (48, 90). Furthermore, elevated levels of collagen IV (91) have 
been noted in bronchoalveolar lavage (BAL) fluids from patients 
with BPD. These observations are supported by microscopic 
studies on patient tissues. Thibeault and colleagues (21) observed 
thickened and disorganized collagen fibers, and a generally dam-
aged collagen network in the lungs of infants diagnosed with 
BPD after positive-pressure ventilation. It was proposed by those 
investigators that enlargement of alveoli due to ventilation leads 
to compression of surrounding ECM structures and damage to 
the collagen and elastin niche, disturbing the normal septation 
process. However, both adult rats (92) and newborn mice (93) 
exposed to sub-lethal normobaric hyperoxia up-regulated col-
lagen I production, assessed by northern blot and immunoblot, 
respectively. In the case of newborn mice, the increased collagen I 
production was attributed to activation of the pro-fibrotic growth 
factor, transforming growth factor (TGF)-β, which stimulated 
collagen production and secretion by fibroblasts. Increased col-
lagen deposition in the lung parenchyma of newborn mice has 
been confirmed in the hyperoxia-based mouse BPD model by 
picrosirius red staining (72, 94). Additionally, total lung collagen 
protein levels were increased by 63% after exposure of developing 
mouse pups to hyperoxia (89). Taken together, these reports make 
a strong case for dysregulated collagen expression in aberrant 
lung development associated with clinical and experimental BPD.
Collagen production under physiological and pathophysi-
ological conditions is regulated by inter alia growth factors, such 
as TGF-β, where in vitro stimulation of primary lung fibroblasts 
drives Col1a1 production (95, 116). This is significant, because 
elevated TGF-β levels were associated with BPD in preterm 
infants (115). TGF-β has also been causally implicated in the 
blunted alveolar development associated with hyperoxia expo-
sure in the mouse hyperoxia model of BPD (117). The connection 
between TGF-β and collagen deposition in the developing lung 
is noteworthy. Over-expression of TGF-β driven by the Scgb1a1 
(encoding surfactant-associated protein C, pro-SPC) promoter in 
a doxycycline-inducible system is sometimes used as an animal 
model of BPD. Over-expression of TGF-β in this model not only 
resulted in blunted alveolarization but also increased deposi-
tion of collagen in the developing septa (118). Furthermore, 
over-expression of TGF-β in the developing lung in utero caused 
pulmonary hypoplasia that was accompanied by thickening of 
the collagen fibers and excessive collagen deposition in the septa 
(119). Exactly how the blunted alveolarization connects with 
perturbed ECM generation, both of which are guided by TGF-β, 
remains to be clarified.
Failed alveolar septation in both clinical and experimental 
BPD is clearly accompanied by changes to collagen production 
and deposition in the lungs. Studies, to date, have addressed 
primarily the fibrillar collagens collagen I and collagen III, 
however, the remaining 26 other collagens have received little or 
no attention. It remains of interest to explore whether perturba-
tions to the expression of those collagens might be associated 
with arrested alveolar development. Similarly, no studies, to 
date, have examined the regulation or activity of the procollagen 
processing proteases, bone morphogenetic protein 1 (BMP-1) 
and ADAM metallopeptidase with thrombospondin type 1 
motif, 2 (ADAMTS2). Both enzymes are required for procollagen 
processing and assembly into fibrils, during lung development.
elastin
Elastic fibers consist of extensively cross-linked elastin and 
fibrillin (28) microfibrils. These structures are associated with 
accessory molecules, including latent TGF-β-binding protein 
(LTBP), microfibril-associated proteins, fibulin, emilin, and 
microfibril-associated glycoprotein (MAGP) family members. 
Elastin fibers are located throughout the developing lung, in the 
developing conducting airways and alveolar ducts, the conduct-
ing vessels, and the developing septa. As illustrated in Figure 1, 
the expression of elastin in mice is dynamically regulated over the 
alveolarization period. Elastin expression dramatically increases 
at a time-point coincident with the “burst” of secondary septa-
tion that drives the formation of the alveoli. Elastin expression 
remains high throughout the secondary septation period [for 
example, in mice, over (P5–P15)] and rapidly decreases once 
alveolarization has been completed (8, 120). However, reactiva-
tion of elastin expression occurs in adult lungs under pathological 
conditions, such as emphysema and pulmonary fibrosis, where 
disorganized elastic fibers have been described (22, 120). The first 
hints that elastin plays a role in lung development included the 
observations that lung elastin levels were modulated as post-natal 
lung development proceeded (39). Additionally, the expression of 
tropoelastin, the “elastin monomer,” was dynamically regulated 
over the course of post-natal lung development in rodents (40, 
41). During lung alveolarization, elastin is specifically deposited 
in “foci” at the tips of developing septa, suggesting a role in the 
process of secondary septation, which generates the alveoli. 
The spatially regulated deposition of elastin that coincides with 
secondary septation has led to the idea that elastin is a driver of 
lung development (121–123).
Further support for a role for elastin in lung development has 
been obtained using elastin-deficient mice. Elastin deficiency 
TABLe 2 | Dysregulation of the expression of extracellular matrix components and remodeling enzymes in clinical bronchopulmonary dysplasia and 
experimental animal models.
eCM component expression in the disease/experimental condition
Bronchopulmonary dysplasia Hyperoxia Mechanical ventilation
Collagen ↑ (48, 91) ↓ (Fibroblasts, in vitro) (95)
↑ (Mouse) (72, 89, 93)
↑ (Rat) (92)
EC-SOD ↓ (Mouse) (55)
Elastin ↓ (Fibroblasts, in vitro) (95) ↑ (Mouse) (23, 99–101)
↓ (Mouse) (89, 96) ↑ (Lamb) (24, 102)
↑ (Mouse) (51, 72, 93, 97) ↑ (Rat) (103)
↑ (Rat) (98)
Fibrillin-1 ↑ (Mouse) (51) ↑ (Mouse) (99)
↑ (Lamb) (24)
EMILIN-1 ↑ (Mouse) (23, 72) ↓ (Mouse) (23)
Fibrillin-2 ↑ (Mouse) (51) ↓ (Mouse) (23, 99)
Fibronectin ↑ (60, 62, 104, 105) ↑ (Mouse) (105)
↑ (Rabbit) (106)
Fibulin-5/DANCE ↑ (Mouse) (51, 72) ↓ (Mouse) (23)
↑ (Rat) (103)
↑ (Lamb) (24)
Integrins ↑ (Mouse) (51)
Lox ↑ (72) ↑ (Mouse) (51, 72, 89) ↑ (Mouse) (23)
↑ (Lamb) (24)
Loxl1 ↑ (72) ↑ (Mouse) (72, 89) ↓ (Mouse) (23)
↑ (Lamb) (24)
↑ (Rat) (103)
Loxl2 ↑ (Mouse) (72, 89)
MMP-1 ↑ (Rat) (92) ↓ (Baboon) (107)
MMP-16 ↓ (Rat) (108)
MMP-2 ↓ (109) ↓ (Rat) (110)
↕ (Rat) (78)
↑ (Rat) (77)
↑ (Mice) (93)
MMP-8 ↑ (111, 112) ↓ (Baboon) (107)
MMP-9 ↓ (Rat) (110) ↑ (Rat) (103)
↕ (Rat) (78) ↑ (Mouse) (100, 101)
↑ (Rat) (77) ↑ (Baboon) (107)
↑ (Mice) (93)
MMP-9:TIMP-1 ↑ (113, 114) ↑ (Baboon) (107)
MT1-MMP ↑ (Rat) (78)
PLOD1 ↑ (Mouse) (80)
PLOD2 ↑ (80) ↑ (Mouse) (80)
PLOD3 ↑ (Mouse) (80)
Tenascin C ↑ (83) ↓ (Fibroblasts, in vitro) (95) ↑ (Rat) (103)
TGF-β ↑ (115) ↑ (Mouse) (51) ↑ (Lamb) (24)
↑ (Rat) (78, 92)
TIMP-1 ↓ (113) ↑ (Fibroblasts, in vitro) (95)
↑ (Rat) (78, 110)
tTG ↑ (85) ↑ (Mouse) (85)
Arrows indicate the direction of dysregulated expression: ↓, down-regulation; ↑, up-regulation; ↕, temporal regulation in either direction over time.
ECM, extracellular matrix; EC-SOD, extracellular superoxide dismutase 3; EMILIN-1, elastin microfibril interfacer 1; LOX, lysyl oxidase; LoxL1, lysyl oxidase-like 1; LoxL2, lysyl 
oxidase-like 2; LTBP2, latent TGF-β-binding protein 2; MMP, matrix metalloproteinase; MT1, membrane-type 1; PLOD, procollagen-lysine, 2-oxoglutarate 5-dioxygenase; TGF-β, 
transforming growth factor-β; TGM2, transglutaminase 2; TIMP, tissue inhibitor of metalloproteinase; tTG, tissue transglutaminase.
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is accompanied by perinatal lethality, and Eln−/− mice exhibit 
arrested perinatal development of the terminal airway branches, 
and enlarged terminal air sacs (124). Elastin haploinsufficient 
(Eln+/−) mice, which express 50% of the elastin seen in wild-type 
mice (125), exhibited normal lung development and normal 
alveolar structures, although there is some evidence that the elas-
tin deposition in Eln−/− mice was abnormal (99). Modulating the 
dose of elastin to <50%, by expressing the human elastin gene in a 
transgenic homozygous-null Eln−/− mouse strain reduced elastin 
levels to 37% of wild-type mouse levels. While transgenic expres-
sion of human elastin rescued the perinatal lethality observed 
in Eln−/− mice, a pronounced blunting of alveolar development 
was noted (125). These data indicate that a baseline threshold of 
elastin abundance is required for normal lung development to 
proceed. All of these observations underscore important roles for 
the correct spatio-temporal production of elastin structures in 
the developing lung.
In the context of lung disease, abnormal elastin fiber structures 
have been observed in the parenchyma of aberrantly developing 
lungs from prematurely born ventilated neonates (126). Parallel 
trends have been observed in animal models of BPD, where 
in response to mechanical ventilation or perinatal exposure to 
hyperoxia, the normally organized deposition of elastin fibers 
into foci at the tips of developing septa is lost. Rather, elastin fibers 
are noted in the walls (not the tips) of the thickened developing 
septa and have been described to be “brush-like,” “thickened,” and 
“loose” (32, 102, 127–129).
The pathological mechanisms behind the disturbed produc-
tion and deposition of elastin in aberrantly developing lungs 
remains to be clarified, however, much work in this area has been 
already done, and remains ongoing. There is a body of evidence 
that suggests that expression of the Eln gene is up-regulated by 
hyperoxia in animal models of BPD, as revealed by real-time 
reverse transcription (RT)-polymerase chain reaction (PCR) 
analysis of mRNA pools from lung homogenates (51, 72, 97). 
The cell types reported to produce elastin in the lung are listed in 
Table 1, which include fibroblasts and smooth muscle cells. How 
hyperoxia modulates Eln gene expression might be attributed to 
growth factor stimulation or inhibition of elastin synthesis. Both 
TGF-β (130, 131) and insulin-like growth factor (IGF) (132) 
stimulated Eln gene expression, whereas some forms of platelet-
derived growth factor (PDGF) suppressed Eln gene expression 
(133). Furthermore, the stability of Eln mRNA was increased by 
TGF-β, without impacting mRNA synthesis by lung fibroblasts 
(134). This is important, since increased TGF-β signaling and lev-
els of TGF-β ligands were associated with experimental (117) and 
clinical BPD (115). Apart from TGF-β, increased IGF levels were 
also associated with experimental (135) and clinical (136) BPD, 
whereas decreased levels of some forms of PDGF were associated 
with clinical BPD (137). Taken together, these data would suggest 
that the pro-elastogenic effects of TGF-β and IGF were promoted, 
while the anti-elastogenic activity of PDGF was blocked during 
arrested alveolarization associated with BPD. These effects may 
also explain the increased abundance of Eln mRNA in the lung in 
hyperoxia-based experimental animal models of BPD.
It might be argued that given the extraordinarily long half-life 
of elastin fibers in the lung [estimated to be several years in the 
mouse (138)], studies on gene expression are less meaningful 
than studies on elastin protein production and organization into 
elastic fibers. Experimental studies on alveolarization tend to 
examine elastin distribution by light microscopy [for example, 
with Hart’s stain (72, 100, 101) or immunohistochemistry (51)], 
and infer elastin abundance from those studies. However, some 
studies have directly addressed insoluble elastin fiber abundance 
biochemically, where, in contrast to elevated mRNA levels, there 
appeared to be a paucity of insoluble elastin in affected lungs, 
assessed by lung desmosine or isodesmosine amounts (89, 96). 
The paucity of elastin was generally accompanied by the clearly 
disorganized structure and distribution of elastin fibers evident in 
the developing septa. This discord between elastin gene expres-
sion (which was increased) and the abundance of insoluble elastin 
(which was decreased) in injured developing lungs (together with 
perturbed elastin fiber structure and distribution) has several 
possible explanations, none of which have yet been experimen-
tally tested. (i) The post-transcriptional regulation of Eln gene 
expression may be affected. For example, translation of mature 
Eln mRNA may be blocked by microRNA species generated in 
response to hyperoxia. Among the microRNA species that have 
been identified the target elastin are miR-29a/b/c (139) and miR-
184, miR-194, miR-299, and miR-376b (http://www.mirbase.
org). The possibility of microRNA regulation of elastin expression 
in the lung has not yet been addressed. Alternatively, the paucity 
of insoluble elastin in the background of increased Eln mRNA 
abundance might be attributed to (ii) defective post-translational 
maturation of elastin during fiber formation, or (iii) increased 
proteolytic degradation of elastin. Concerning post-translational 
maturation of elastin fibers, many accessory proteins have been 
identified that can associate with elastin fibers. These include the 
glycoproteins emilin (140), fibulin (29), LTBP (141), and MAGP 
family members (142). Discordant expression of these elastin 
fiber-associated proteins may result in unstable or malformed 
fiber structures. Indeed, Richard Bland has proposed that the 
uncoupling of elastin synthesis and assembly is a pathogenic 
contributor to disordered elastin fiber generation in BPD (23). 
Elastin fibers with abnormal physical properties may also result 
from the aberrant activity of the elastin maturation machinery, 
including the hydroxylation and cross-linking activities of lysyl 
hydroxylases and lysyl oxidases, respectively. These possibilities 
are discussed below. Alternatively, changes in the proteolytic 
capacity of injured, developing lungs may impact elastin fiber pro-
duction or turnover, either directly (by proteolysis) or indirectly 
(by regulating the activity of mediators of elastin production). It is 
these lines of enquiry that are likely to further our understanding 
of why elastin organization is disturbed, and what impact this has 
on alveolarization in the developing lungs.
Some reports addressing the role of serine proteinases in the 
regulation of elastin production have already yielded exciting 
data. The group of Richard Bland has examined the utility of 
blocking serine peptidase activity in the context of BPD. Serine 
peptidase activity, such as that of neutrophil elastase, was elevated 
in the lung in clinical and experimental BPD. Mechanical ventila-
tion of mouse pups with 40% O2 increased elastin degradation 
and disturbed septal elastin fiber deposition in the mouse lung, 
which was prevented by intratracheal administration of the 
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neutrophil elastase inhibitor elafin (100). Thus, inhibition of neu-
trophil elastase activity [and probably matrix metalloproteinase 
(MMP)-9 activity as well, since MMP-9 can also be inhibited by 
elafin] partially restored proper elastin structures and improved 
lung alveolarization in this model. Furthermore, inhibition of 
neutrophil elastase activity blunted inflammation and inhibited 
the generation of active TGF-β that was proposed to be released 
from the ECM by proteolysis. In support of this idea, transgenic 
over-expression of elafin in the vascular endothelium similarly 
protected mice against the aberrant alveolarization and per-
turbed elastin assembly caused by mechanical ventilation (101). 
Subsequent exciting work by Keith Tanswell’s group has similarly 
reported that neutrophil elastase inhibition with sivelestat also 
improved lung structure and elastin deposition in the hyperoxia-
based BPD animal model in mice (98). In this study, it is also 
noted that administration of anti-elastin antibodies in the mouse 
hyperoxia model of BPD prevented inflammatory infiltration 
into the lungs. Thus, these investigators raised the exciting pos-
sibility that neutrophil elastase-generated elastin fragments acted 
as pro-inflammatory matrikines (143), suggesting a mechanism 
by which hyperoxia exposure provoked lung inflammation. These 
data also raise further questions, for example, while neutrophil 
elastase inhibition clearly improved alveolarization in two differ-
ent animal models of BPD, the underlying mechanisms remain 
unclear. The organization of elastin fibers was improved in both 
models, and inflammation and TGF-β activation was blunted. 
However, it remains unclear whether the improved alveolariza-
tion was a direct or indirect consequence of elastase inhibition 
(144). For example, was the generation of elastin fragments suffi-
cient to provoke lung inflammation, or did the elastase-mediated 
activation of TGF-β play a role in this process as well? Elastase 
inhibition in the background of TGF-β neutralization would go 
some distance to resolving these open questions.
One vexing controversy in the lung alveolarization field is: 
are elastin protein levels elevated or reduced in the aberrantly 
developing lungs in the hyperoxia-based animal models of BPD? 
In mechanically ventilated lambs and mice, multiple reports 
document increased Eln mRNA levels, which were consistent with 
increased elastin protein levels in the lung (23, 102). However, 
this was not the case with normobaric hyperoxia-based models 
in mice, where many reports also confirm that Eln mRNA levels 
were up-regulated by hyperoxia exposure, but there appeared to 
be a paucity of lung insoluble elastin, when (iso)desmosine was 
used as a surrogate for mature, insoluble elastin fibers (89, 96). 
However, these observations are complicated by other reports 
of increased elastin protein in the hyperoxia models, employing 
either slot–blots (98) or immunoblots (51, 93). This controversy 
must still be resolved. These discordant data might be attribut-
able to the methodology employed, where protein extraction by 
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) for the blot-based protocols may have a different capac-
ity for the extraction of insoluble elastin compared with the 
whole-lung hydrolyzates used in the (iso)desmosine approaches. 
Irrespectively, neither approach address the quantification of 
elastin specifically in the developing septa, which represents a 
major limitation of all of the approaches currently employed.
The current state of the field seems to suggest less lung elastin 
and more lung collagen, at least in the hyperoxia models of BPD. 
Given that, collagen imparts rigidity and elastin imparts elastic-
ity to the lung, a shift in the collagen:elastin ratio may impact 
alveologenesis. This shift in collagen:elastin ratio may be as much 
as threefold increased by hyperoxia exposure (89). This is likely to 
dramatically impact lung compliance, and given the importance 
of the physical forces generated by breathing motions in “pulling 
the alveoli into shape,” a shift in the lung collagen:elastin ratio 
cannot be discounted as a possible contributing factor to lung 
alveolar development.
ADDiTiONAL STRUCTURAL 
COMPONeNTS OF THe eCM
Fibrillins
Fibrillins are elastin-binding glycoproteins (Figure 2) that make 
up the bulk of the microfibril component of elastic fibers, and act 
as a scaffold for elastic fiber deposition (28). Fibrillin-1 (Fbn1) 
and fibrillin-2 (Fbn2) are the main microfibril proteins (145). 
Fbn1 is clearly important for alveolarization and the structural 
homeostasis of the alveoli, since Fbn1−/− mice exhibited an 
alveolarization defect (146), and fibrillin fibers were fragmented 
and disorganized in emphysema (147). In addition to imparting 
structural properties to elastic fibers, fibrillins may also help to 
mediate elastic fiber assembly, such as lysyl oxidase cross-linking 
of elastin fibers (28), which is thought to be highly relevant to 
lung development (27, 64, 72, 89, 148, 149). Similarly, Fbn1 
played a role in anchoring LTBP to ECM components (58). 
Changes in fibrillin expression have been noted in animal models 
of BPD. In mechanically ventilated mice, the ratio of Fbn1:Fbn2 
was increased, with elevated Fbn1 expression and reduced Fbn2 
expression noted (23, 99). By contrast, in the mouse hyperoxia 
model of BPD, the expression of both Fbn1 and Fbn2 mRNA was 
elevated (51). With these ideas in mind, disturbances to fibril-
lin expression may impact lung development either by directly 
modulating the physical properties of elastic fibers or by altering 
TGF-β dynamics in the ECM. These ideas await experimental 
investigation.
Tenascin C
Tenascins are a five-member family of large ECM glycoproteins, 
with tenascin C (Tnc), which is expressed in myofibroblasts, 
and endothelial, smooth muscle, and type II cells (81, 83), being 
the most studied in lung development (84) (Table 1). Tnc was 
comparatively highly expressed during human and animal devel-
opment, including in the lung, particularly during the pseudog-
landular and canalicular stages (84), at sites of active branching. 
Tnc is important for alveolarization, since Tnc−/− mice exhibited 
an alveolarization defect (150). Along these lines, administration 
of dexamethasone to developing mouse pups blunted alveolariza-
tion, which was accompanied by decreased Tnc expression (56), 
although the impact of dexamethasone on Tnc expression was not 
causally linked to the blunted alveolarization. In contrast to these 
findings, TNC expression was elevated in the lungs of patients 
Elasn Collagen
Fibrillin-2
Fibrillin-1
Fibulin-5
EMILIN-1
LOXL1 Fibronecn
Hyaluronic 
acid
Fibulin-1
Fibrin
Heparin
Integrins
Tenascin C
EC-SOD
LTBP
LOX
Intramolecular and 
intermolecular cross-linking
FiGURe 2 | interactions between components of the extracellular matrix in the lung. The primary interacting molecules for elastin and fibronectin are 
collected together above the respective target molecules in the downward-pointing block arrows. Abbreviations: EC-SOD, extracellular superoxide dismutase; 
EMILIN-1, elastin microfibril interfacer 1; LOX, lysyl oxidase; LOXL1, lysyl oxidase-like 1; LTBP, latent transforming growth factor-β-binding protein.
December 2015 | Volume 2 | Article 918
Mižíková and Morty The ECM in BPD
Frontiers in Medicine | www.frontiersin.org
with BPD (83), which is consistent with the ability of TGF-β to 
drive Tnc expression in primary mouse fibroblasts in vitro (95). 
Tnc clearly plays a role in normal lung alveolarization; however, 
a causal role for changes on Tnc expression in aberrant lung 
alveolarization has yet to be demonstrated.
Fibronectin
Fibronectin (Fn1) is a large (440 kDa) glycoprotein dimer, con-
sisting of two almost identical subunits. Fn1 has been reported 
both as a soluble form in plasma and as an insoluble form associ-
ated with the ECM, where Fn1 binds collagen (Figure 2), as well 
as Tnc, and other ECM components (151). Fn1 is expressed in the 
lung (152), in interstitial fibroblasts, endothelial cells, and smooth 
muscle cells, but not in epithelial cells (Table 1). Fn1 expression 
was highest during lung development, and very low in adult lung 
tissue (152). Fn1−/− mice exhibited early embryonic lethality 
(153), and a role for Fn1 in lung development has not been dem-
onstrated but is assumed. Several studies have documented the 
increased expression of Fn1 in clinical BPD, including in plasma, 
in endotracheal aspirates, and in BAL fluid (60, 104, 154, 155), 
as well as in lung tissue (60). This is consistent with the ability of 
TGF-β to drive Fb1 expression in lung fibroblasts (152). To date, 
no causal role for Fb1 in normal or aberrant lung development 
has been demonstrated. However, one exciting observation has 
suggested that decreased miR-206 expression in both clinical 
and experimental BPD may underlie the increased levels of FB1 
noted in the lungs of BPD patients (60, 105), since FB1 has been 
described to be a target of miR-206 (105). Furthermore, miR-206 
levels were decreased, whereas Fb1 levels were increased in lungs 
from hyperoxia-exposed mouse pups (105). Taken together, these 
data make a compelling argument for the miR-206/Fb1 axis in 
aberrant alveolarization associated with BPD, although this idea 
requires experimental demonstration.
Fibulins and emilins
Fibulins and emilins promote proper elastin fiber formation, by 
mediating protein–protein interactions between ECM proteins, 
or between the ECM and ECM remodeling enzymes, such as 
lysyl oxidases (156). Fibulins are small calcium-dependent 
glycoproteins that bind elastin (Figure 2). Fibulin-5 (Fbln5; also 
called developmental arteries and neural crest EGF-like protein, 
DANCE) has been reported to play a role in lung alveolarization. 
Fbln5−/− mice exhibited short, fragmented, and thickened elastin 
fibers, as well as a pronounced arrest of alveolarization (29, 157). 
No studies have examined a role for fibulins in clinical BPD; 
however, studies in animal models of BPD consistently revealed 
increased expression of Fbln5 in mouse pups exposed to hyperoxia 
(51, 72). Since TGF-β can drive Fbln5 expression (158), increased 
Fbln5 production after hyperoxia exposure may have been due 
to the attendant increased TGF-β signaling seen in this model 
(95). Changes in fibulin expression also appear to be sensitive to 
mechanical ventilation, where Martin Post’s group demonstrated 
that Fbln5 expression was impacted by the duration and intensity 
of tidal volume ventilation, and breathing frequency, when rats 
were mechanically ventilated with room air (103). Conversely, 
Richard Bland’s group did not detect any impact of mechanical 
ventilation on Fbln5 expression when mice were ventilated with 
room air; however, ventilation with 40% O2 reduced Fbln5 levels 
in the lung, which was accompanied by blunted alveolarization. 
While the Fbln5−/− mouse studies have implied a role for Fbln5 
in alveolarization, the impact of increased Fbln5 expression on 
secondary septation and the development of the alveoli await 
December 2015 | Volume 2 | Article 919
Mižíková and Morty The ECM in BPD
Frontiers in Medicine | www.frontiersin.org
demonstration. By way of speculation, Fbln5 promoted activation 
of MMP-2 and MMP-9 (159), which have also been associated with 
clinical and experimental BPD (see below). This, together with 
the possibility that Fbln5 over-expression might disturb elastic 
fiber formation, and might regulate the association of superoxide 
dismutase (SOD) (160) and lysyl oxidase-like 1 (LoxL1) (64) with 
the ECM, suggests avenues by which fibulin over-expression may 
influence lung development.
Like fibulins, emilins are a related group of elastic fiber-
associated proteins (Figure 2), which impact elastogenesis, and 
have been reported to be expressed in the lung (161). Elastin 
microfibril interfacer 1 (Emilin-1) expression has not been 
studied in clinical BPD. However, Emilin1 expression has been 
reported to be dysregulated in animal models of BPD, including 
the hyperoxia exposure [Emilin1 mRNA expression up-regulated; 
(23, 72)] and mechanical ventilation [Emilin1 protein expression 
down-regulated; (23)] in mice. Emilin1−/− knockout mice do exist 
(162), although no lung phenotype has been reported. However, 
the reported dramatic (2,000-fold) up-regulation of Emilin1 
expression in c-Jun N-terminal kinase (Jnk) knockout mice was 
reported to be accompanied by an alveolarization defect, perhaps 
implicating Emilin1 in the alveolarization process (163), although 
a dramatic up-regulation of Fbln1, Fbln5, and Eln expression was 
also noted in that study.
Latent TGF-β-Binding Proteins
The LTBP family consists of four extracellular MAGPs (164), 
which interact with, thereby modulate the activity of TGF-β. 
Ltbp1, Ltbp3, and Ltbp4 are reported to all associate with the 
small latent complex of TGF-β ligands and latency-associated 
propeptide (LAP), to generate the large latent complex (164). 
The LTBP family members are structurally related to fibrillins 
and were reported to interact with the ECM and play a role in 
ECM assembly. Ltbp1−/− mice exhibited perinatal lethality with 
heart defects, while a lung phenotype was not studied or reported 
(165). By contrast, both Ltbp3−/− and Ltbp4−/− mice exhibited 
an arrest of alveolarization (166) that was more pronounced in 
Ltbp4−/− mice (167). Ltbp4, which is known to bind Fbln5 (167), 
is believed to independently modulate elastogenesis and TGF-β 
activity, and thus, regulate lung development (168). The function 
of Ltbp2 remains elusive (164), but it has been suggested that 
Ltbp2 plays a TGF-β-independent role in elastogenesis (141), and 
Ltbp2 has been co-localized with fibronectin and Fbn1 in lung 
fibroblast cultures (58). Studies on Ltbp2 are complicated by the 
embryonic lethality reported in Ltbp2−/− mice (169). Interestingly, 
despite a clear role in alveolarization, no studies, to date, have 
examined the expression of LTBP family members in clinical or 
experimental BPD. These exciting studies await experimental 
investigation.
Polysaccharide Conjugates
Heparin, heparan sulfate, hyaluronic acid (hyaluronan), and 
chondroitin sulfate are polysaccharides or polysaccharide con-
jugates that have been reported to be mediators of lung alveo-
larization (170–172). Proteins carrying these conjugates, such as 
syndecan, which contains both heparan sulfate and chondroitin 
sulfate, exhibited molecular polymorphism  –  notably changes 
in the length of the heparin sulfate chains – over the course of 
lung development (173), implicating a role for heparan sulfate 
proteoglycans in lung development.
Temporal and spatial changes in glycosaminoglycan syn-
thesis by lung fibroblasts have also been reported during lung 
development (174). Notably, fibroblasts in close proximity to the 
epithelium secreted hyaluronan, while more distant fibroblasts 
produced heparan sulfate and chondroitin sulfate during the 
pseudoglandular stage of lung development. During later stages 
of lung development, these fibroblasts switched to producing 
more hyaluronan, which was coincident with the thinning of 
the alveolar walls during the canalicular and later developmental 
stages. These authors postulated that developmentally regulated 
glycosaminoglycan generation by lung fibroblasts facilitated lung 
epithelial–mesenchymal interactions, which guided aspects of 
lung development (174).
Heparin and heparan sulfate have been reported to be the pre-
dominant glycosaminoglycans in epithelial basement membranes 
of the alveolus, and granules associated with collagen fibers of the 
basement membrane contained proteoglycan aggregates, which 
included chondroitin or dermatan sulfate (175). Heparan sulfate 
has been localized in the basement membrane during the embry-
onic, canalicular, and later phases of lung development (176). 
Heparan sulfate has received particular attention as a growth 
factor-binding protein, particularly in the context of fibroblast 
growth factor (FGF)-10, where Wellington Cardoso’s group has 
provided evidence that FGF-10 induction of local budding during 
early lung development is directed by developmentally regulated 
regional patterns of heparan sulfate sulfation (177). This idea has 
also been extended to cytokines, such as interleukin (IL)-1 in 
the developing chick lung (178), as well as members of the bone 
morphogenetic protein (BMP) family (179).
Several studies in transgenic mice have highlighted causal 
roles for enzymes of the heparan sulfate biosynthetic pathway 
in lung development. For example, deletion of N-deacetylase/N-
sulfotransferase (heparan glucosaminyl) 1 (Ndst1) led to 
pulmonary hyperplasia and acute respiratory distress in mice, 
possibly due to decreased surfactant production as a result of 
type II cells to mature (180). Similarly, deletion of glucuronyl 
C5-epimerase (Glce) in mice caused embryonic lethality, and 
stunted embryonic lung development, which was accompanied 
by a total loss of l-iduronic acid in heparan sulfate conjugates 
(181). Specifically concerning late lung development, defects 
in the development of the airspaces have been noted in both 
heparan sulfate 6-O-sulfotransferase 1 (Hs6st1) (182) and sul-
fatase 2 (Sulf2) (183) knockout mice. Apart from mice lacking 
enzymes involved in the heparan sulfate biosynthetic pathway, 
mice lacking heparan sulfate proteoglycans also exhibit lung 
development phenotypes. For example, deletion of glypican-3, a 
member of a family of heparan sulfate proteoglycans linked to 
the cell surface through a glycosyl-phosphatidylinositol anchor, 
generated abnormal lung structures in mice (184). These stud-
ies validated the earlier suggestion that heparin and heparan 
sulfate are mediators of lung development, although most work 
has been confined to the earlier stages of lung development that 
precede alveolarization. The generation of antibodies that detect 
specific heparan sulfate epitopes has facilitated the identification 
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of spatio-temporal changes in heparan sulfate structure during 
normal lung development, and aberrant lung development 
associated with congenital diaphragmatic hernia (CDH) (65, 
185), which will facilitate further mechanistic work in this area. 
To date, exactly how these structural abnormalities to heparan 
sulfate proteoglycans results in disturbed alveolar structure 
remains to be clarified.
In addition to heparan sulfate proteoglycans, some work 
in embryonic lung explants has also revealed a role for chon-
droitin sulfate proteoglycans in early lung development (186). 
Furthermore, an interesting connection with inflammatory 
cells has been made, with the suggestion that CD44-positive 
macrophages, which take up hyaluronan, may regulate the 
steady-state levels of hyaluronan during lung development (187). 
Further work in this area should examine how defined alterations 
to proteoglycan structures direct proper development of the lung. 
The existence of transgenic mice and monoclonal antibodies that 
allow the specific detection of proteoglycan structures will facili-
tate these efforts. Additionally, no studies, to date, have examined 
changes in the expression of proteoglycan biosynthetic enzymes, 
or proteoglycan structures, in animal models of BPD.
eCM-iNTeRACTiNG MOLeCULeS
integrins
Integrins are large heterodimeric transmembrane glycoproteins 
associated with various elements of the ECM. Integrin ligands 
include collagen I, Tnc, Fb1, laminins, TGF-β, and tissue trans-
glutaminase (Tgm2), among many others. Each integrin dimer 
consists of a single α and β subunit. There are many integrin subu-
nits, with 18 α and 8 β subunits having been identified in humans, 
to date (67). Expression of integrins is known to be dynamically 
regulated during lung development, where integrin-mediated 
cell–ECM interactions are known to play an important role (68, 
188). Integrin expression has been noted during alveolarization, 
with the α2, α3, α6, and β1 subunits having been reported to be 
expressed in the bronchial and alveolar epithelium during the 
alveolar stage of lung development, as well as in adult lungs. 
By contrast, the α4 subunit was reported to be expressed in the 
respiratory epithelium only during lung development and has 
not been detected in adult lungs (68, 69, 188). The fibronectin 
receptor, integrin α8β1 (189) has been demonstrated to play a 
particularly noteworthy role in early and late lung development, 
where the Lawrence Prince’s group demonstrated that in  utero 
exposure of developing embryos to bacterial lipopolysaccharide 
(LPS) caused a reduction in expression of Itga8, which encodes 
the α8 integrin subunit, in mesenchymal cells (30). Thus, these 
authors examined lung structure in Itga8−/− mice, which exhib-
ited a pronounced disturbance to the developing lung structure, 
including lobar fusion and alveolar simplification. Additionally, 
elastin fibers in these mouse lungs were described to be “wavy 
and short.” This led these authors to suggest that integrin–ECM 
interactions played a notable role in late lung development. This 
idea is supported by observations made in the mouse hyperoxia 
BPD model, where increased expression of Itgav, encoding the 
αv integrin subunit [which also binds fibronectin; (67)], was 
noted (51), and was accompanied by impaired alveolarization 
and increased Fbln5 expression and TGF-β activity, and aberrant 
elastin fiber deposition. These studies have opened up an exciting 
new avenue, that is, the role of integrin-mediated ECM interac-
tions in the regulation of alveolarization.
extracellular Superoxide Dismutase
Extracellular superoxide dismutase (EC-SOD or Sod3), is one of 
three forms of SOD, a group of antioxidant enzymes representing 
the major cellular defense against the superoxide anion O2
⋅( ) (54, 
190). EC-SOD is the only ECM-related antioxidant and has been 
reported to be the most abundant SOD in the lung (191). EC-SOD 
was reported to be expressed primarily in vessels, large airways, 
and alveolar septa. EC-SOD binds heparin (192) and heparan 
sulfate proteoglycans on the cell surface, and components of the 
ECM (54). EC-SOD binds collagen I (Figure 2) and is thought to 
protect against oxidative damage to collagen I (193). EC-SOD is 
also known to bind to tropoelastin, a process that is mediated by 
Fbln5 (160). EC-SOD is believed to play a role in protecting the 
ECM from oxidative damage, since reactive oxygen species (ROS) 
drive elastin degradation and increased collagen cross-linking 
(194, 195). Thus, EC-SOD might protect the developing and adult 
lung from oxidative damage (54), since EC-SOD was reported 
to be expressed throughout life (196), although EC-SOD protein 
expression and activity were blunted by hyperoxia exposure in 
adult mice (197). Along these lines, adult Sod−/− mice exhibited 
increased sensitivity to hyperoxic damage, with reduced survival 
and more pronounced alveolar edema, compared to wild-type 
mice; thus, supporting a role for EC-SOD in protection against 
oxidative damage to the lung (198). In support of this idea, over-
expression of EC-SOD in transgenic neonatal mice protected 
against the damaging effects of hyperoxia on lung alveolarization 
(196), and expression of EC-SOD in a mouse lung epithelial 
cell-line protected against oxidative damage-induced cell death 
(55). The protective effects of EC-SOD over-expression on lung 
epithelial cells has also been demonstrated in vivo in hyperoxia-
exposed newborn mice (199). None of these studies addressed 
collagen or elastin fiber integrity.
A wide spectrum of other ECM-interacting proteins still 
remains to be studied in the context of lung alveolarization. These 
proteins include the MAGP family members (142), as well as the 
small leucine-rich proteoglycans, such as decorin and related 
molecules, which play key roles in driving collagen fiber forma-
tion (200, 201). These future studies will no doubt add to the list 
of ECM-associated proteins that impact normal and aberrant late 
lung development.
eCM ReMODeLiNG eNZYMeS
Matrix Metalloproteinases and Their 
inhibitors
Matrix metalloproteinases are a large family of endopeptidases 
responsible for ECM breakdown and remodeling, which are 
necessary processes for proper formation of the ECM (9, 202). 
Different MMPs preferentially degrade different components of 
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the ECM, with MMP-1 and MMP-8 active against fibrillar colla-
gens, and MMP-2 and MMP-9 preferentially active against base-
ment membrane collagen (collagen IV), fibronectin, and elastin 
(77, 203–206). The proteolytic activity of MMPs can be regulated 
by MMP binding to cognate inhibitors, such as tissue inhibitor of 
metalloproteinases (TIMPs) (110, 207) (Figure 3). The expression 
of MMPs in the lung is known to be dynamically regulated over 
the course of lung development (Figure  1), with a progressive 
decrease in MMP-2 and MMP-14 [also called membrane-type-1 
(MT1)-MMP] expression, but a progressive increase in MMP-9 
expression between E10 and P21. These trends imply a role in lung 
alveolarization (9, 75, 78). Expression of MMP-2 and MMP-14 
has been noted in airway and alveolar epithelial cells, endothelial 
cells, and fibroblasts (74–76), whereas MMP-9 was reported to be 
expressed in epithelial cells, fibroblasts, and inflammatory cells, 
including neutrophils and alveolar macrophages (61, 77, 79) 
(Table 1). MMP expression in the lung was driven by exposure 
of adult (77) and neonatal (93) rodents to hyperoxia. Similarly, 
elevated MMP expression has been noted in endotracheal aspi-
rates or BAL fluid from preterm infants with BPD (109, 111–113). 
MMPs also played a role in alveolar destruction in experimental 
emphysema in mice (208). MMPs might impact alveolarization 
directly, through degradation of ECM components, or indirectly, 
through activation of growth factor pathways. For example, 
MMP-9 activated TGF-β signaling, which in turn stimulated 
lung fibroblasts to contract (61, 209). MMP-9 appeared to be able 
to influence lung alveolarization, since Mmp9−/− mice exhibited 
worsened lung development, in a mouse model where lung 
alveolarization was blocked by over-expression of IL-1β (210). 
In an alternative hyperoxia-based BPD model, Mmp9−/− mice 
were protected against the blunted alveolarization usually seen in 
the mouse hyperoxia BPD model (93). The reasons for these two 
discordant observations are currently unclear, however, may be 
related to the different models employed. Along the same lines, 
Mmp14−/− mice initially exhibited a 40% decrease in alveolar 
surface area compared to wild-type mice early during post-natal 
lung development (76), which was accompanied by thickened 
elastin fibers. By contrast, Mmp2−/− mice exhibited a “delayed” 
alveolarization, where an alveolarization defect was noted at 
P7, but alveolarization was normalized at P14 (76). It would be 
interesting to explore the impact of hyperoxia or mechanical ven-
tilation of the Mmp2−/− and Mmp14−/− mice on alveolarization.
Several studies have addressed MMP expression in clinical 
BPD cases, where reduced MMP-2 levels were noted in endotra-
cheal aspirates (109) and plasma (211), but increased MMP-8 
levels were noted in endotracheal aspirates (111) and BAL fluid 
(112) from preterm infants with BPD. Increased MMP-9:TIMP-1 
ratios have also been detected in BAL fluids from preterm infants 
that developed BPD (114) (Figure 4). Additionally, Ekekezie and 
coworkers (113) observed an increased MMP-9:TIMP-1 ratio in 
endotracheal aspirates from BPD patients, which correlated with 
poor patient outcome. These trends largely parallel observations 
made in animal models of BPD, where increased levels of MMP-2 
and MMP-9 proteins were noted in hyperoxia-exposed mouse 
pups (93). Similarly, MMP-9 levels were modulated in the lungs 
of hyperoxia-exposed rats (78), and increased MMP-9 levels and 
an increased MMP-9:TIMP-1 ratio were noted in a premature 
baboon BPD model (107). Not all trends in MMP expression 
are consistent between investigations. For example, Hosford and 
co-workers reported the decreased expression of MMP-9 and 
increased expression of TIMP-1 in the rat hyperoxia model of 
BPD (110), which was also accompanied by blunted alveolariza-
tion. These discordant observations might be attributed to the 
extraordinary variation in the application of the BPD models: 
(i) newborn rats exposed to >90% O2 for 9 days versus (ii) ven-
tilated, premature baboons versus (iii) rats exposed to >95% O2 
between P4 and P14. Irrespectively, the general trend is toward 
increased MMP-9 activity in aberrantly developing lungs.
Lysyl Oxidases
Lysyl oxidases constitute a family of five members: the arche-
typical lysyl oxidase (Lox) and four lysyl oxidase-like enzymes 
(Loxl1–LoxL4) (212, 213). All lysyl oxidases catalyze the oxida-
tive deamination of lysine and hydroxylysine residues, generating 
reactive semialdehydes, which then form intramolecular and 
intermolecular covalent cross-links in both elastin and collagen 
molecules (212, 213). Lysyl oxidases have been reported to play 
an essential role in normal lung development and have been 
implicated in the pathogenesis of several lung diseases, including 
pulmonary hypertension (73), lung adenocarcinoma (214), and 
BPD (72). Lysyl oxidases are known to play an important role 
in organogenesis, with Lox−/− mice exhibiting perinatal lethal-
ity, ostensibly due to a failure of the cardio-respiratory system 
(215, 216). Furthermore, Lox has been specifically implicated in 
the development of the respiratory system, where Lox has been 
reported to be required for the integrity of elastic and collagen 
fibers in multiple tissues (27). Interestingly, genetic ablation 
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exclusively of Lox expression significantly reduced total lysyl 
oxidase activity, suggesting that Lox is the primary contributor 
out of the five family members, to lysyl oxidase-mediated effects. 
In Lox−/− mouse lungs, both desmosine and hydroxyproline levels 
were decreased relative to wild-type mice (216). While viable, 
Loxl1−/− mice exhibited connective tissue weakness, and devel-
oped pelvic organ prolapse and cutis laxa (64). Furthermore, 
Loxl1−/− mice exhibited alveolar simplification and reduced lung 
desmosine levels, implying a role in lung development, as well as 
perturbed elastin fiber structures throughout the organism (64).
Lysyl oxidase expression has been studied in animal models of 
BPD. Increased Lox and Loxl1 expression has been noted in the 
lungs of preterm ventilated lambs (24). Lox expression was also 
increased by mechanical ventilation in mouse pups (23), but lung 
Loxl1 levels were reduced in mechanically ventilated mice (23). 
Elevated lysyl oxidase activity (72, 89, 94), and elevated Lox and 
Loxl1 levels (72, 89) were detected in newborn mice exposed to 
normobaric hyperoxia. This has led some investigators to propose 
that the ECM in affected lungs might be “over cross-linked,” and 
thus excessively stabilized, which has been proposed to be a 
potential contributing factor in arrested alveologenesis associ-
ated with clinical and experimental BPD (72, 89). Consistent 
with elevated Lox expression and activity, exposure to hyperoxia 
also generated increased amounts of insoluble collagen and the 
dihydroxylysinonorleucine (DHLNL) collagen cross-link, as well 
as an increased DHLNL:hydroxylysinonorleucine (HLNL) ratio, 
and disordered elastin organization in the alveolar septa (89). To 
address a causal role for lysyl oxidases in blunted alveolarization 
in the hyperoxia BPD model, newborn mice were treated with 
the pan-lysyl oxidase inhibitor β-aminopropionitrile (BAPN), 
which did not improve lung alveolarization, but did improve 
elastin organization assessed by visual inspection (89). This might 
indicate that the partial normalization of elastin organization in 
developing septa alone (through normalization of lysyl oxidase 
activity) was not sufficient to normalize lung alveolarization in 
the mouse hyperoxia BPD model. Several questions regarding 
lysyl oxidases and alveolarization come to mind, among them: 
what role do the different lysyl oxidases play in lung development, 
and in which tissues? Lysyl oxidases are expressed in several 
different cell types (Table 1), and it may be that different lysyl 
oxidases have different contributions to lung alveolarization, 
acting in different cell types. The generation of conditional, 
inducible deletions of the various lysyl oxidase genes would help 
to address this question. Additionally, “non-matrix” roles for 
lysyl oxidases should also be considered, where lysyl oxidases 
have been reported to modulate gene regulation in the nucleus, 
for example, the expression of COL3A1 (217). This has revealed 
nuclear functions  –  primarily of LoxL2  –  which modulated 
epigenetic effects in the nucleus by deamination of trimethylated 
Lys4 in histone H3, which was linked to transcriptional repression 
(218). Furthermore, LoxL2 regulated keratinocyte differentiation 
independent of lysyl oxidase catalytic activity (219). Similar 
studies have yet to be performed with other lysyl oxidases, but 
highlight possible roles for lysyl oxidases in lung alveolarization 
that are not related to ECM cross-linking.
Lysyl Hydroxylases
The ability of lysyl oxidases to generate covalent cross-links 
requires lysine or hydroxylysine residues in ECM substrates. 
These hydroxylysine residues are generated by another family of 
enzymes, the lysyl hydroxylases (officially named procollagen-
lysine, 2-oxoglutarate 5-dioxygenases, or PLODs) (220), which 
consist of three family members: PLOD1–PLOD3. A role for lysyl 
hydroxylases in organ development was underscored by the early 
embryonic lethality of Plod3−/− mice (221), while Plod1−/− mice 
were viable, but exhibited vascular pathology and abnormal 
collagen fiber structure (222). This family of ECM-modifying 
enzymes is relatively poorly characterized. Some evidence does 
exist illustrating that lysyl hydroxylases play a role in aberrant late 
lung development, both in humans and in mice. A recent study 
by Witsch and colleagues (80) revealed that the lung expression 
of PLOD family member PLOD2 was up-regulated in premature 
infants with BPD. Furthermore, Plod1, Plod2, and Plod3 expres-
sion was elevated in the lungs of mice in the hyperoxia BPD model 
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(80), and the elevated Plod2 expression was mediated by TGF-β. 
These data indicate that the lysyl hydroxylases may play a role 
in normal and abnormal lung development, and this possibility 
awaits experimental attention.
Transglutaminases
The transglutaminases constitute an eight-member family 
of calcium-dependent enzymes, which cross-link collagens 
and fibronectin, among other proteins (223). Of the transglu-
taminases, largely transglutaminase 2 (Tgm2; also called tissue 
transglutaminase, tTG) has been studied in lung disease and 
was reported to be expressed in fibroblasts, as well as epithelial, 
endothelial, and smooth muscle cells (85, 224). In addition to 
cross-linking activity, Tgm2 is an integrin-binding adhesion 
co-receptor for fibronectin (225). Tgm2 has also been implicated 
in lung fibrosis (86, 226, 227), allergy (87), cystic fibrosis (228, 
229), and pulmonary hypertension (230). Tgm2 has further 
been credited with a role in organogenesis (231), including lung 
development (232). In preterm infants with BPD, TGM2 mRNA 
levels were elevated (85), which was also seen in the lungs of 
hyperoxia-exposed newborn mice with experimental BPD (85). 
In the case of hyperoxia-exposed newborn mice, increased Tgm2 
levels were driven by TGF-β, most likely in lung epithelial cells. 
This is particularly noteworthy because not only can TGF-β drive 
Tgm2 expression but Tgm2 can also activate TGF-β (233), sug-
gesting a possible vicious circle of Tgm2 expression and TGF-β 
activation in aberrant lung alveolarization. These studies indicate 
that changes in transglutaminase expression are associated with 
normal and aberrant alveolarization; however, a causal role for 
transglutaminases in lung development has yet to be experimen-
tally documented. The existing Tmg2−/− knockout mice would be 
an ideal starting point for these studies (234).
PeRSPeCTive
Given that, the ECM plays a pivotal role in lung development, 
it comes as no surprise that perturbations to ECM production 
and remodeling accompany defective secondary septation and 
aberrant alveolarization associated with BPD. Identification of 
the perturbations to ECM organization that play a causal role 
in aberrant alveolarization would assist in our understanding of 
the pathological processes that disturb late lung development. 
Equally important is the delineation of pathogenic pathways that 
drive these causal disturbances to ECM structure.
Roles for ECM structural proteins and ECM remodeling 
enzymes in lung alveolarization have been identified using gene 
knockout approaches. These studies have provided a very solid 
foundation for future work but are complicated by the pre- or 
peri-natal lethal phenotype of some knockout mice. This has 
been partially remedied by the parallel over-expression of human 
genes, or genes with altered promoter activity, in the background 
of a homozygous-null strain (such as the expression of the human 
ELN gene in Eln−/− mice, described above), which overcome the 
lethality of the homozygous-null mutants, and facilitated further 
studies on the gene products of interest. However, this has been 
more the exception than the norm. Additionally, it is widely 
recognized that the discrete expression of particular genes, in 
particular, cell types at particular stages of lung development is 
the basis of the highly coordinated program of the generation of 
a very complex organ (1, 2). This makes the use of constitutive 
global knockout mouse strains problematic.
Rapidly evolving mouse transgenic technology makes an 
increasing number of conditional-ready gene-deletion strains 
available through the use of floxed alleles. In combination with 
inducible Cre-recombinase systems, these conditional strains 
become inducible, conditional strains, which facilitate gene 
deletion in developing mouse pups at particular time points dur-
ing post-natal lung development, in restricted cell types. These 
approaches rely largely on the use of doxycycline-inducible rtTA 
(tetO)7-Cre and tamoxifen-inducible CreERT2 systems. These 
inducible, conditional-ready mouse strains will prove invaluable 
in assessing how the temporal and tissue-specific expression of 
particular genes during lung development impacts lung develop-
ment per se (235). Among the drawbacks of this approach are the 
limitations of some floxed allele strains, which would have to be 
created de novo, and also, the lack of – or technical difficulties with 
the use of – some driver lines. For example, no suitable driver line 
currently exists that can exclusively target lung fibroblasts, or that 
can discriminate between airway and vascular smooth muscle 
cells (235). Remaining with transgenic mice, most studies, to 
date, have evaluated the loss of a particular gene on lung devel-
opment. However, particularly in the context of animal models 
of BPD, genes might be over-expressed or up-regulated, rather 
than down-regulated. As such, to be able to “phenocopy” a lung 
phenotype by over-expressing a gene of interest, in the correct cell-
type at the correct time, would go a long way to validate candidate 
pathogenic mediators of arrested alveolarization. Along these 
lines, many knockout and pharmacological intervention studies 
have identified new “players” in normal lung alveolarization 
(such as LTBP and elastin and collagen cross-linking enzymes), 
but a contribution to pathological lung development in animal 
models of BPD has not been undertaken. These exciting studies 
may well reveal new pathogenic pathways that drive aberrant 
lung alveolarization.
While elastin has received a tremendous amount of atten-
tion as a regulator of lung development, the collagens remained 
largely neglected. Since many candidate pathogenic mediators 
(such as elastin cross-linking enzymes) also influence collagen 
structure and function, it would be interesting to explore roles 
for disturbed collagen organization during lung development. 
Along these lines, the ratio of elastin:collagen is also notewor-
thy. In the hyperoxia models of BPD, there is a reported shift 
toward an increased collagen:elastin ratio. This would impact 
lung rigidity and elasticity, and thus lung development, which is 
dependent on physical forces generated by, for example, breath-
ing motions.
Animal models of BPD have proved very important for the 
identification of candidate pathogenic mediators of normal and 
aberrant late lung development. These studies are often not fol-
lowed up with validation studies that pin-point a role (if any) for 
a particular candidate mediator that exhibited changes in gene or 
protein expression in a BPD model. These studies are important, 
since changes in the gene or protein expression of a particular 
molecule may be (i) epiphenomenal (i.e., that the molecule in 
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question was a bystander without any role in the alveolarization 
process), (ii) causal (i.e., that molecule in question was a mediator 
of arrested alveolarization), or (iii) reparative (i.e., that molecule 
in question mediated a lung defense or repair program that was 
engaged during aberrant alveolarization, which aimed to restore 
proper alveolarization). It is very important to determine which 
of these three categories a “candidate” mediator of aberrant lung 
development falls into.
Interestingly, in many studies, once a candidate mediator of 
aberrant lung alveolarization was identified in an animal model of 
BPD, much effort was then expended on identifying how the can-
didate mediator impacted ECM structures during alveolarization. 
Rather, less energy is usually invested in understanding how the 
expression of the candidate mediator was altered by the injurious 
stimulus (for example, inflammation, hyperoxia, or mechanical 
ventilation). The identification of such proximal pathways would 
be important in a translational sense, where addressing the very 
proximal causes of arrested lung development might be thera-
peutically targeted, ultimately in affected patients. With this in 
mind, physical forces and oxidative stress might be good starting 
points to understand the activation of pathways that produce or 
remodel the ECM. Furthermore, ECM structures have recently 
been credited with a role in driving pluripotent cell differentiation 
in acellular lung scaffolds (236). Thus, how the ECM may shape 
stem cell niches in the developing lung, and direct phenotypic 
transformation of the constituent cell types of the developing 
lung are further areas that will no doubt receive attention in the 
coming years.
With the rapidly expanding repertoire of genetic tools, and the 
development of state-of-the-art methodology to study both lung 
alveolar architecture and the biochemical nature of the ECM, we 
have never been better positioned to explore the complex interac-
tions of the ECM during lung alveolarization. It is clear that there 
is much exciting work to be done!
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